InMed Pharmaceuticals 대차 대조표 상태

재무 상태 기준 확인 4/6

InMed Pharmaceuticals 의 총 주주 지분은 $9.2M 이고 총 부채는 $0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 $11.8M 및 $2.6M 입니다.

주요 정보

부채 비율

US$0

부채

이자 보상 비율	n/a
현금	US$6.61m
주식	US$9.21m
총 부채	US$2.62m
총 자산	US$11.82m

최근 재무 상태 업데이트

Recent updates

InMed Pharmaceuticals GAAP EPS of -$33.17, revenue of $1.09M

Sep 26

InMed Pharma announces $6M private placement

Sep 09

InMed Pharma says phase 2 trial for skin disorder cannabinol cream can now include teens

Jul 25

InMed Pharmaceuticals gets non-compliance notice on Nasdaq minimum bid price requirement

Jul 13

InMed To Acquire Rare Cannabinoid Manufacturer BayMedica

Jul 02

InMed's INM-755 CBN cream did not introduce any delay in normal wound healing

Jan 08

재무 상태 분석

단기부채: INM 의 단기 자산 ( $8.7M )이 단기 부채( $2.0M ).

장기 부채: INM 의 단기 자산( $8.7M )이 장기 부채( $644.9K ).

부채 대 자본 내역 및 분석

부채 수준: INM 부채가 없습니다.

부채 감소: INM 5년 전에 부채가 없었습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: INM 현재 무료 현금 흐름을 기준으로 1년 미만의 cash runway를 보유하고 있습니다.

예측 현금 활주로: 무료 현금 흐름이 매년 9.8 %의 역사적 비율로 계속 감소할 경우 INM 의 현금 활주로는 1년 미만입니다.

InMed Pharmaceuticals 대차 대조표 상태

재무 상태 기준 확인 4/6

주요 정보

최근 재무 상태 업데이트

InMed Pharmaceuticals Inc. announced delayed annual 10-K filing

InMed Pharmaceuticals Inc. announced delayed 10-Q filing

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

InMed Pharmaceuticals Inc. Receives Written Notice from the Listing Qualifications Department Staff of the Nasdaq Capital Market

InMed Pharmaceuticals Announces Voluntary Delisting from TSX

Recent updates

High number of new and inexperienced directors

InMed Pharmaceuticals Inc. Announces the Appointment of Dr. Barry Greenberg to Its Scientific Advisory Board

New major risk - Financial position

Full year 2024 earnings released: US$1.01 loss per share (vs US$3.25 loss in FY 2023)

InMed Pharmaceuticals Inc., Annual General Meeting, Dec 18, 2024

InMed Pharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of $1.03019 million.

New major risk - Financial position

Third quarter 2024 earnings released: US$0.18 loss per share (vs US$0.60 loss in 3Q 2023)

InMed Pharmaceuticals Inc. Announces Additional Preclinical Data Demonstrating INM-901'S Positive Pharmacological Effects in the Potential Treatment of Alzheimer's Disease

Second quarter 2024 earnings released: US$0.18 loss per share (vs US$0.91 loss in 2Q 2023)

InMed Pharmaceuticals Inc. Announces Chief Financial Officer Changes, Effective February 20, 2024

Inmed Pharmaceuticals Inc. Announces the Launch of Inm-089

InMed Pharmaceuticals Inc. Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023

InMed Pharmaceuticals Inc. announced that it has received CAD 5.000002 million in funding

Inmed Pharmaceuticals Inc. Selects A Lead Alzheimer's Disease Drug Candidate, Named INM-901

InMed Pharmaceuticals Inc. announced that it expects to receive CAD 2.500001 million in funding

InMed Pharmaceuticals Inc. announced delayed annual 10-K filing

Full year 2023 earnings released: US$3.25 loss per share (vs US$33.17 loss in FY 2022)

InMed Pharmaceuticals Inc., Annual General Meeting, Dec 19, 2023

InMed Pharmaceuticals Inc. announced delayed 10-Q filing

InMed Pharmaceuticals Inc. Appoints Jonathan Tegge as Interim Chief Financial Officer

InMed Pharmaceuticals Inc. announced that it has received CAD 6.000011 million in funding

Inmed Pharmaceuticals Inc. Announces Promotion of Sarah Li to Controller and Principal Accounting Officer

Inmed Pharmaceuticals Inc. Provides Update on Management Changes

InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada Alliance Grant Funding

InMed Pharmaceuticals Inc., Annual General Meeting, Dec 15, 2022

InMed Pharmaceuticals GAAP EPS of -$33.17, revenue of $1.09M

InMed Pharmaceuticals Inc. to Report Fiscal Year 2022 Results on Sep 23, 2022

InMed Pharmaceuticals Inc. announced that it has received $6.000007 million in funding

InMed Pharmaceuticals Inc. announced that it expects to receive $6.000007 million in funding

InMed Pharma announces $6M private placement

InMed Pharmaceuticals Inc. Appoints Nicole Lemerond to Its Board of Directors

InMed Pharmaceuticals Inc. Provides an Update on Its Phase 2 Clinical Trial

InMed Pharma says phase 2 trial for skin disorder cannabinol cream can now include teens

InMed Pharmaceuticals Inc. Announces Michael Woudenberg Has Been Appointed Chief Operating Officer

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

InMed Pharmaceuticals gets non-compliance notice on Nasdaq minimum bid price requirement

InMed Pharmaceuticals Inc. Receives Written Notice from the Listing Qualifications Department Staff of the Nasdaq Capital Market

InMed Pharmaceuticals Inc. Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions

InMed Pharmaceuticals Inc. announced that it has received $1.499999 million in funding

InMed Pharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of $3.500002 million.

InMed Pharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of $4.25 million.

Inmed Pharmaceuticals Inc. Announces Appointment of Bryan Baldasare to Its Board of Directors Effective May 13, 2022

InMed Pharmaceuticals Inc. Cannabidivarin, Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector

InMed Pharmaceuticals Inc. Announces Board Changes

InMed Pharmaceuticals Inc. to Report Q2, 2022 Results on Feb 15, 2022

InMed Launches Cannabicitran (CBT), Expanding Its Rare Cannabinoid Portfolio for the Health and Wellness Sector

InMed Pharmaceuticals Inc. announced that it has received $12 million in funding

InMed To Acquire Rare Cannabinoid Manufacturer BayMedica

InMed Pharmaceuticals Inc. (NasdaqCM:INM) entered into a nonbinding letter of intent to acquire BayMedica Inc. for $4.7 million.

Inmed Pharmaceuticals Increases Cannabinoid Yield to 5 G/L with IntegraSyn in Advance of Commercial Scale Production

InMed Pharmaceuticals Announces Voluntary Delisting from TSX

InMed Pharmaceuticals Achieves 2G/L Cannabinoid Yield with Integrasyn

InMed Pharmaceuticals Inc. announced that it has received $4.4625 million in funding

New 90-day high: US$5.35

InMed Pharmaceuticals Inc. announced that it expects to receive $4.499998 million in funding

InMed Pharmaceuticals Inc. Announces Top-Line Results from Its 755-102-HV Phase 1 clinical trial

InMed's INM-755 CBN cream did not introduce any delay in normal wound healing

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

현금 런웨이 분석

건강한 기업 발견하기